Latest News
AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s disease.
The placebo-controlled study enrolled 34 participants, with 25 receiving ACI-7104.056 and ni
Via MarketBeat · September 26, 2026
The chipmaker already pledged up to $10 billion to the Claude maker last year. What would a second check buy?
Via The Motley Fool · September 26, 2026
Nike's fiscal Q1 results may not be enough to boost Nike stock.
Via The Motley Fool · September 26, 2026
Schwab U.S. Dividend Equity ETF is a solid high-yield option, but you may want to consider PepsiCo, Enterprise, and Realty Income instead.
Via The Motley Fool · September 26, 2026
The supply chain of loans could be in a crunch during an economic calamity.
Via The Motley Fool · September 26, 2026
The "force majeure" shows how complicated it has become to construct a data center on time.
Via The Motley Fool · September 26, 2026
That rule makes a lot of sense for this exchange-traded fund once you understand why it's in place.
Via The Motley Fool · September 26, 2026
BTCS (NASDAQ:BTCS) Chief Executive Officer Charles Allen outlined the company’s strategy to expand its decentralized finance operations, use on-chain borrowing to manage capital and emphasize gross profit as a key performance measure during a Water Tower Research Virtual Insights Conference.
Allen
Via MarketBeat · September 26, 2026
AGNC Investment invests in residential mortgages.
Via The Motley Fool · September 26, 2026
PepsiCo is muddling through a rough patch, but it is severely lagging this key competitor.
Via The Motley Fool · September 26, 2026
Finding the right hair salon can sometimes feel harder than finding the perfect hairstyle. You may walk into a salon with a clear idea of what you want, on
Via Talk Markets · September 26, 2026

Matching a fragrance to a person isn't really about gender or age brackets — it's about temperament. Some people want to smell like a quiet room; others wa
Via Talk Markets · September 26, 2026
The dominant home improvement retailer can be a top choice for income investors.
Via The Motley Fool · September 26, 2026
These three dividend stocks give investors a mix of everyday demand, steady cash flow, and long-term payout growth.
Via The Motley Fool · September 26, 2026
Universal (NYSE:UVV) outlined its strategy to build on its global leaf tobacco business while expanding its plant-based ingredients platform during a Sidoti conference presentation led by Chairman, President and CEO Preston Wigner.
Wigner described Universal as a business-to-business agriproducts c
Via MarketBeat · September 26, 2026
Remarkably, the data storage company is priced at close to value-stock levels.
Via The Motley Fool · September 26, 2026
The long-term outlook for GE Vernova appears positive, and with an investing plan in place, investors can take full advantage of the potential upside.
Via The Motley Fool · September 26, 2026
AMD looks like a great buy, while ARM Holdings' stock has gotten ahead of itself.
Via The Motley Fool · September 26, 2026
These companies pay growing monthly dividends.
Via The Motley Fool · September 26, 2026
The market certainly has high hopes for the company.
Via The Motley Fool · September 26, 2026
Solar industry executives said near-term demand remains strong despite policy uncertainty, tariffs and supply-chain adjustments, with data centers, manufacturing growth and energy-storage deployment expected to support continued investment in renewable generation.
Speaking at BNP Paribas’ Power Up
Via MarketBeat · September 26, 2026
Filing too soon could reduce your benefits substantially.
Via The Motley Fool · September 26, 2026
Eli Lilly's share price climb has decelerated in 2026.
Via The Motley Fool · September 26, 2026
BWX Technologies, Mercury Systems, and Howmet Aerospace show strong backlog, revenue growth, and raised guidance as defense spending rises, though their stock performances vary widely.
Via MarketBeat · September 26, 2026
Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.
Via The Motley Fool · September 26, 2026